What's new — Rheumatoid arthritis¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 2 |
| last 2 months | 15 |
| last 3 months | 18 |
| last 6 months | 28 |
| last year | 40 |
| older than a year | 242 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-06 | Outcomes of Tapering Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial — Arthritis Rheumatol ([PMID 42839723](https://pubmed.ncbi.nlm.nih.gov/42839723/){target="_blank" rel="noopener"}) | treat-to-target-and-remission |
| 2026-10-02 | Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis — Biomark Res ([PMID 42907925](https://pubmed.ncbi.nlm.nih.gov/42907925/){target="_blank" rel="noopener"}) | biomarkers-and-tissue-precision |
| 2026-10-01 | Efficacy of tapering biologics and JAK inhibitors in rheumatoid arthritis: A systematic review and meta-analysis — Reumatol Clin (Engl Ed) ([PMID 42963167](https://pubmed.ncbi.nlm.nih.gov/42963167/){target="_blank" rel="noopener"}) | jak-inhibitors-and-targeted-therapy, treat-to-target-and-remission |
| 2026-10-01 | Divergent approaches to rheumatoid arthritis-associated interstitial lung disease: a comparative analysis of international clinical practice guidelines — Rheumatol Int ([PMID 42888356](https://pubmed.ncbi.nlm.nih.gov/42888356/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-01 | Senescent-like activated naive B cells contribute to progression to clinical rheumatoid arthritis — Nat Aging ([PMID 42875583](https://pubmed.ncbi.nlm.nih.gov/42875583/){target="_blank" rel="noopener"}) | preclinical-autoimmunity-and-prevention |
| 2026-10-01 | Lung ultrasound as part of a diagnostic algorithm to detect interstitial lung disease in rheumatoid arthritis patients at risk — Clin Exp Rheumatol ([PMID 42873714](https://pubmed.ncbi.nlm.nih.gov/42873714/){target="_blank" rel="noopener"}) | ra-associated-interstitial-lung-disease |
| 2026-10-01 | JAK Inhibitor Cycling Shows Higher Drug Retention than Biologic Switching Following First JAK Inhibitor Failure in Rheumatoid Arthritis — Joint Bone Spine ([PMID 42869207](https://pubmed.ncbi.nlm.nih.gov/42869207/){target="_blank" rel="noopener"}) | difficult-to-treat-and-refractory-ra |
| 2026-10-01 | Temporal Patterns of Outcomes After DMARD Tapering or Withdrawal in Rheumatoid Arthritis With Sustained Disease Control: A Systematic Review and Meta-Analysis — Clin Transl Sci ([PMID 42836514](https://pubmed.ncbi.nlm.nih.gov/42836514/){target="_blank" rel="noopener"}) | treat-to-target-and-remission |
| 2026-10-01 | Comparative Safety of JAK versus TNF Inhibitors in Older Adults with Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study — J Rheumatol ([PMID 42823079](https://pubmed.ncbi.nlm.nih.gov/42823079/){target="_blank" rel="noopener"}) | jak-inhibitors-and-targeted-therapy |
| 2026-10-01 | First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes — Rheumatology (Oxford) ([PMID 42755040](https://pubmed.ncbi.nlm.nih.gov/42755040/){target="_blank" rel="noopener"}) | biologic-dmards |
| 2026-09-03 | Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA) — Front Immunol ([PMID 42877103](https://pubmed.ncbi.nlm.nih.gov/42877103/){target="_blank" rel="noopener"}) | jak-inhibitors-and-targeted-therapy |
| 2026-09-02 | Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis — Ann Rheum Dis ([PMID 42881069](https://pubmed.ncbi.nlm.nih.gov/42881069/){target="_blank" rel="noopener"}) | treat-to-target-and-remission |
| 2026-09-02 | Recommendations of the Argentine Society of Rheumatology for the Treatment of Patients With Rheumatoid Arthritis. Update 2025 Part II. Definitions in the Context of RA Treatment and Therapeutic Strategies for Special Situations and Comorbidities — J Clin Rheumatol ([PMID 42767235](https://pubmed.ncbi.nlm.nih.gov/42767235/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-01 | Comparative efficacy and safety of disease-modifying antirheumatic drugs tapering strategies in sustained-remission rheumatoid arthritis: Systematic review and network meta-analysis — Semin Arthritis Rheum ([PMID 42843067](https://pubmed.ncbi.nlm.nih.gov/42843067/){target="_blank" rel="noopener"}) | treat-to-target-and-remission |
| 2026-09-01 | Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study — Respir Med ([PMID 42722091](https://pubmed.ncbi.nlm.nih.gov/42722091/){target="_blank" rel="noopener"}) | clinical-trials-landscape, ra-associated-interstitial-lung-disease |
| 2026-08-03 | Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials — Lancet Rheumatol ([PMID 42546722](https://pubmed.ncbi.nlm.nih.gov/42546722/){target="_blank" rel="noopener"}) | jak-inhibitors-and-targeted-therapy |
| 2026-08-02 | Risk prediction rules in individuals at risk of rheumatoid arthritis: systematic review and validation using the APIPPRA cohort — EULAR Rheumatol Open ([PMID 42676706](https://pubmed.ncbi.nlm.nih.gov/42676706/){target="_blank" rel="noopener"}) | preclinical-autoimmunity-and-prevention |
| 2026-08-02 | CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial — Nat Med ([PMID 42661098](https://pubmed.ncbi.nlm.nih.gov/42661098/){target="_blank" rel="noopener"}) | clinical-trials-landscape, difficult-to-treat-and-refractory-ra |
| 2026-08-01 | Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis-a case series — Ann Rheum Dis ([PMID 42595657](https://pubmed.ncbi.nlm.nih.gov/42595657/){target="_blank" rel="noopener"}) | difficult-to-treat-and-refractory-ra |
| 2026-08-01 | Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #3 — J Rheumatol ([PMID 41921998](https://pubmed.ncbi.nlm.nih.gov/41921998/){target="_blank" rel="noopener"}) | guidelines |
| 2026-07-02 | Recommendations of the Argentine Society of Rheumatology for the Treatment of Patients With Rheumatoid Arthritis: 2025 Update Part I — J Clin Rheumatol ([PMID 42507767](https://pubmed.ncbi.nlm.nih.gov/42507767/){target="_blank" rel="noopener"}) | guidelines |
| 2026-07-02 | Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial — Lancet Rheumatol ([PMID 42392130](https://pubmed.ncbi.nlm.nih.gov/42392130/){target="_blank" rel="noopener"}) | clinical-trials-landscape, overview, preclinical-autoimmunity-and-prevention |
| 2026-07-01 | Definition and prevalence of residual disease in inflammatory arthritis: a systematic literature review and meta-analysis — Semin Arthritis Rheum ([PMID 42485861](https://pubmed.ncbi.nlm.nih.gov/42485861/){target="_blank" rel="noopener"}) | treat-to-target-and-remission |
| 2026-07-01 | Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis — Cochrane Database Syst Rev ([PMID 42440279](https://pubmed.ncbi.nlm.nih.gov/42440279/){target="_blank" rel="noopener"}) | difficult-to-treat-and-refractory-ra |
| 2026-07-01 | 2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management — Int J Rheum Dis ([PMID 42362943](https://pubmed.ncbi.nlm.nih.gov/42362943/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-05 | Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement — Lancet Respir Med ([PMID 42248165](https://pubmed.ncbi.nlm.nih.gov/42248165/){target="_blank" rel="noopener"}) | guidelines, ra-associated-interstitial-lung-disease |
| 2026-06-03 | Rheumatoid factor production is genetically and molecularly distinct from rheumatoid arthritis — J Clin Invest ([PMID 42378266](https://pubmed.ncbi.nlm.nih.gov/42378266/){target="_blank" rel="noopener"}) | preclinical-autoimmunity-and-prevention |
| 2026-06-03 | Risk of disease flare and clinical reversibility following discontinuation versus dose reduction of biological DMARDs in Rheumatoid arthritis: A systematic review and meta-analysis — Semin Arthritis Rheum ([PMID 42269230](https://pubmed.ncbi.nlm.nih.gov/42269230/){target="_blank" rel="noopener"}) | treat-to-target-and-remission |
| 2026-04-02 | Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence — Semin Arthritis Rheum ([PMID 42034889](https://pubmed.ncbi.nlm.nih.gov/42034889/){target="_blank" rel="noopener"}) | jak-inhibitors-and-targeted-therapy |
| 2026-04-01 | Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): An Official 2025 ALAT Clinical Practice Guideline — Arch Bronconeumol ([PMID 42034552](https://pubmed.ncbi.nlm.nih.gov/42034552/){target="_blank" rel="noopener"}) | guidelines |
| 2026-04-01 | Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis — Ann Rheum Dis ([PMID 41997804](https://pubmed.ncbi.nlm.nih.gov/41997804/){target="_blank" rel="noopener"}) | guidelines |
| 2026-03-01 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update — Ann Rheum Dis ([PMID 41826212](https://pubmed.ncbi.nlm.nih.gov/41826212/){target="_blank" rel="noopener"}) | guidelines |
| 2026-03-01 | A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis — Arthritis Rheumatol ([PMID 40884017](https://pubmed.ncbi.nlm.nih.gov/40884017/){target="_blank" rel="noopener"}) | clinical-trials-landscape, preclinical-autoimmunity-and-prevention |
| 2026-01-02 | Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial — Lancet Rheumatol ([PMID 41576971](https://pubmed.ncbi.nlm.nih.gov/41576971/){target="_blank" rel="noopener"}) | clinical-trials-landscape, overview, preclinical-autoimmunity-and-prevention |
| 2026-01-02 | ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease — Eur Respir J ([PMID 40907995](https://pubmed.ncbi.nlm.nih.gov/40907995/){target="_blank" rel="noopener"}) | guidelines, ra-associated-interstitial-lung-disease |
| 2025-12-02 | Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial — Nat Med ([PMID 41429981](https://pubmed.ncbi.nlm.nih.gov/41429981/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2025-12-02 | Serious Infection Risk With TNF Inhibitors vs. JAK Inhibitors in Rheumatoid Arthritis: A Nationwide Claims-Based Cohort Study — Clin Pharmacol Ther ([PMID 41422438](https://pubmed.ncbi.nlm.nih.gov/41422438/){target="_blank" rel="noopener"}) | jak-inhibitors-and-targeted-therapy |
| 2025-11-03 | Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence — Ann Rheum Dis ([PMID 41188120](https://pubmed.ncbi.nlm.nih.gov/41188120/){target="_blank" rel="noopener"}) | difficult-to-treat-and-refractory-ra |
| 2025-11-02 | Rheumatoid arthritis-associated interstitial lung disease: clinical predictive model and external validation — Respir Res ([PMID 41299487](https://pubmed.ncbi.nlm.nih.gov/41299487/){target="_blank" rel="noopener"}) | extra-articular-and-comorbid-disease, ra-associated-interstitial-lung-disease, red-flags-and-safety-concerns |
| 2025-11-01 | Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis — Lancet Rheumatol ([PMID 41240967](https://pubmed.ncbi.nlm.nih.gov/41240967/){target="_blank" rel="noopener"}) | guidelines |
Trials — what has moved¶
43 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 4 |
| trial records updated in the last month | 11 |
| trial records updated in the last 2 months | 19 |
| trial records updated in the last 3 months | 21 |
| trial records updated in the last 6 months | 21 |
| trial records updated in the last year | 24 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participant | PHASE2 | 251 | Percentage of Participants Achieving ACR20 at Week 12 | 4 | 63 | 0 |
| 2025-01-08 | Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Ex | PHASE2 | 20 | Correlation Between Joint-specific Tilmanocept Uptake and CD206 Expres | 1 | 12 | 0 |
| 2023-11-21 | Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthri | PHASE2 | 144 | Number of Participants Who Developed Clinically-Apparent Rheumatoid Ar | 10 | 56 | 1 |
| 2021-08-17 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibit | PHASE4 | 4372 | Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin | 1132 | 3291 | 153 |
| 2014-04-08 | Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab | PHASE3 | 12 | Percent Change From Baseline in Synovial TNFa, CXCL13, IL-8, IL-6, IL- | 0 | 3 | 0 |
| 2010-03-23 | Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE | PHASE2 | 24 | American College of Rheumatology (ACR) 20 at Week 12 | 2 | 21 | 0 |
| 2009-11-19 | Study of Abatacept Versus Placebo to Assess the Prevention of Rheumato | PHASE2 | 56 | Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) b | 2 | 29 | 0 |
24 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| treat-to-target-and-remission | 2026-10-06 | 7 | 43 |
| biomarkers-and-tissue-precision | 2026-10-02 | 1 | 42 |
| biologic-dmards | 2026-10-01 | 1 | 38 |
| difficult-to-treat-and-refractory-ra | 2026-10-01 | 5 | 41 |
| guidelines | 2026-10-01 | 11 | 50 |
| jak-inhibitors-and-targeted-therapy | 2026-10-01 | 6 | 42 |
| preclinical-autoimmunity-and-prevention | 2026-10-01 | 6 | 42 |
| ra-associated-interstitial-lung-disease | 2026-10-01 | 5 | 40 |
| clinical-trials-landscape | 2026-09-01 | 6 | 38 |
| overview | 2026-07-02 | 2 | 38 |
| extra-articular-and-comorbid-disease | 2025-11-02 | 1 | 38 |
| red-flags-and-safety-concerns | 2025-11-02 | 1 | 35 |
| genetics-environment-and-mucosal-origins | 2025-08-01 | 0 | 38 |
| synovial-immunobiology | 2025-07-02 | 0 | 36 |
| patient-experience-and-advocacy | 2025-05-01 | 0 | 39 |
| conventional-dmards | 2025-04-08 | 0 | 37 |
| classification-and-diagnosis | 2024-06-02 | 0 | 38 |
| epidemiology-and-burden | 2024-06-02 | 0 | 38 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.